Study record managers: refer to the Data Element Definitions if submitting registration or results information. Drug: Crenezumab Crenezumab will be administered subcutaneously every 2 weeks or intravenously every 4 weeks for at least weeks. Drug: Placebo Placebo matched to crenezumab will be administered subcutaneously every 2 weeks or intravenously every 4 weeks for at least weeks. Placebo Comparator: Non-carriers of Mutation: Placebo Participants will receive placebo subcutaneously every 2 weeks or intravenously every 4 weeks for at least weeks.
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Search for terms x. COVID is an emerging, rapidly evolving situation. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : February 11, Study Description.
This randomized, double-blind, placebo-controlled, parallel group, adaptive study will evaluate the efficacy and safety of crenezumab versus placebo in individuals who carry the PSEN1 EA autosomal-dominant mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD.
